Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.

Investors have bought into the promise of CRISPR technology for years. The ability to target and edit genes to treat cancer ...

CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline ...

Indian American researcher developing a novel type of living T cell-based therapy to tackle obesity-induced diabetes ...

Citi's 2026 Virtual Oncology Leadership Summit February 18, 2026 10:45 AM ESTCompany ParticipantsSamarth Kulkarni - CEO ...

The cardiology landscape is rapidly evolving. Novel risk factors and new tools are reshaping CV risk assessment and ...

Eli Lilly (NYSE:LLY) reached a second milestone in its CRISPR gene editing collaboration with Scribe Therapeutics, advancing ...

Scientists are testing whether gene editing might offer a one-time fix for high cholesterol, and approaches being developed ...

With over years of experience analyzing healthcare and life sciences markets, I have witnessed the pharmaceutical industry ...

BOSTON, MA / ACCESS Newswire / February 17, 2026 / Bioxytran, Inc. ("Bioxytran" or the "Company"), a biotechnology company developing galectin-targeting carbohydrate technologies with applications ...

Antibiotic resistance is racing toward a global crisis, with “superbugs” projected to cause over 10 million deaths annually ...